What is the 13F Pro Quality Score for TARS?

13F Pro ranks Tarsus Pharmaceuticals, Inc. (TARS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TARS's current score at https://13fpro.ai/research/TARS (free sign-up required for the full ranking).

Which hedge funds own the most TARS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TARS include Deep Track Capital,, BlackRock,, RTW INVESTMENTS,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TARS as soon as new 13F filings post.

Where does 13F Pro source TARS data?

All Tarsus Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Tarsus Pharmaceuticals, Inc. files with the SEC under CIK 1819790. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TARS in?

Tarsus Pharmaceuticals, Inc. (TARS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TARS research updated on 13F Pro?

TARS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tarsus Pharmaceuticals, Inc.(TARS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1819790 TARS stock profile & AI dashboard →

13F Pro Quality Score

40.8/100

Rank #1,918 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.1/100

Profitability

19.6/100

Balance Sheet

16.1/100

Earnings Quality

30.0/100

Free Cash Flow

16.4/100

Institutional Flow

88.5/100

Revenue Scale

35.5/100

Dilution Risk

17.7/100

TARS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tarsus Pharmaceuticals, Inc. (TARS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TARS at 40.8/100 on a 32-signal composite quality model, placing it at rank #1,918 of 2,879 stocks — the bottom half of the AI-ranked universe. TARS scores in the top quartile across revenue growth (99.1), institutional flow (88.5). Areas of concern include balance sheet strength (16.1) and free cash flow (16.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Tarsus Pharmaceuticals, Inc. reports quarterly revenue of $162.1M, net income of $-7.0M, free cash flow of $-30.5M. Top institutional holders of TARS by reported 13-F value include Deep Track Capital,, BlackRock,, RTW INVESTMENTS,, based on the most recent SEC filings. TARS trades on the Nasdaq exchange and files with the SEC under CIK 1819790. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TARS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tarsus Pharmaceuticals, Inc. directly from SEC EDGAR. Tarsus Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 5 and 87 since 2022, currently 40.8 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Tarsus Pharmaceuticals, Inc.

Quirks, history, and lore behind TARS — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company headquartered in Southern California, focused on developing treatments for eye diseases.
2
The Numbers
A late-stage clinical company that attracted a multi-billion-dollar acquisition offer from a larger pharma player — not bad for a firm with a very lean product pipeline.
3
The History
Founded in the 2010s, it moved quickly through clinical development by targeting an underserved and common eye condition that most people have heard of but few treatments address well.
4
The Secret
Its lead drug candidate targets Demodex blepharitis — yes, that's a mite infestation of your eyelids — which turns out to affect millions of people worldwide.
5
The Lore
Eli Lilly agreed to acquire this company for roughly $1.4 billion, recognizing that tiny eyelid mites represent a surprisingly large commercial opportunity.
6
The Giveaway
Its FDA-approved drug XDEMVY is the first-ever treatment approved for Demodex blepharitis — and its ticker symbol is literally a nod to its ancient Greek anatomical namesake.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$162.1M

Net Income

Q1 2026

$-7.0M

Free Cash Flow

Q1 2026

$-30.5M

D/E Ratio

Q1 2026

0.21

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2487.0% YoY

$451.4MFY 2025

FY17 —FY21 $57.0MFY23 $17.4MFY25 $451.4M

Net Income

+51.4% YoY

$-66.0MFY 2025

FY17 —FY21 $-13.8MFY23 $-135.9MFY25 $-66.0M

Operating Income

+50.4% YoY

$-71.0MFY 2025

FY17 —FY21 $-12.2MFY23 $-143.2MFY25 $-71.0M

EPS (Diluted)

+65.6% YoY

$-1.59FY 2025

FY17 —FY21 $-0.67FY23 $-4.62FY25 $-1.59

Total Assets

+111.7% YoY

$562.2MFY 2025

FY17 —FY21 $178.9MFY23 $265.5MFY25 $562.2M

Total Debt

+142.9% YoY

$72.4MFY 2025

FY17 —FY21 $0.00FY23 $29.8MFY25 $72.4M

Op. Cash Flow

+89.4% YoY

$-12.5MFY 2025

FY17 —FY21 $3.7MFY23 $-117.5MFY25 $-12.5M

Metric	FY 2025	FY 2023	FY 2021	FY 2017
Revenue	$451.4M +2487.0%	$17.4M -69.4%	$57.0M	—
Net Income	$-66.0M +51.4%	$-135.9M -882.8%	$-13.8M	—
Operating Income	$-71.0M +50.4%	$-143.2M -1077.6%	$-12.2M	—
EPS (Diluted)	$-1.59 +65.6%	$-4.62 -589.6%	$-0.67	—
Total Assets	$562.2M +111.7%	$265.5M +48.4%	$178.9M	—
Total Debt	$72.4M +142.9%	$29.8M	$0.00	—
Operating Cash Flow	$-12.5M +89.4%	$-117.5M -3234.8%	$3.7M	—

AI Insight: TARS Financial Trends

Tarsus revenue nearly quadrupled from $41M to $162M in seven quarters while net losses shrank from $33M to $7M, signaling rapid path toward profitability.

• Revenue surged from $41M in Q2 2024 to $162M in Q1 2026, a ~295% increase over seven quarters.

• Net loss narrowed sharply from $33M in Q2 2024 to $7M in Q1 2026, reflecting strong operating leverage.

• Operating cash flow turned positive in Q3 2025 ($18M) and Q4 2025 ($19M) before dipping to -$25M in Q1 2026.

• Total debt held flat at $72M throughout, with equity rising from $225M in Q4 2024 to $349M in Q1 2026.

⚠ Operating cash flow reverted to -$25M in Q1 2026 after two positive quarters — watch whether this reflects seasonal working capital or a structural reversal.

⚠ Company remains operating-loss negative at -$6M in Q1 2026; sustained profitability depends on continued revenue ramp.

⚠ Equity jumped $117M between Q4 2024 and Q1 2025, suggesting a capital raise; dilution risk warrants monitoring.

AI Insight: TARS Ratio Trends

Tarsus has compressed operating losses from -81.6% in Q2 2024 to -3.8% in Q1 2026, signaling a rapid march toward breakeven.

• Operating margin improved dramatically from -81.6% in Q2 2024 to -3.8% in Q1 2026 — a 77.8pp recovery over seven quarters.

• ROIC tightened from -41.1% in Q2 2024 to -5.8% in Q1 2026, reflecting sharply better capital efficiency as revenue scales.

• D/E ratio has been stable, ranging narrowly between 0.21 and 0.32, with no meaningful leverage buildup over the period.

⚠ All profitability metrics remain negative; sustained breakeven depends on continued revenue growth without cost re-acceleration.

⚠ TTM operating margin of -9.5% is wider than the Q4 2025 quarterly read of -5.3%, hinting at possible seasonality or Q1 2026 softness.

Get alerted when TARS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tarsus Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TARS

Deep Track Capital, LP
$252.5M3,600,000 sh
BlackRock, Inc.
$249.2M3,552,612 sh
RTW INVESTMENTS, LP
$234.7M3,346,025 sh
Paradigm Biocapital Advisors LP
$179.7M2,562,154 sh
JANUS HENDERSON GROUP PLC
$157.2M2,240,963 sh
MORGAN STANLEY
$136.4M1,944,272 sh
VANGUARD CAPITAL MANAGEMENT LLC
$123.5M1,760,541 sh
JENNISON ASSOCIATES LLC
$120.1M1,712,124 sh
Assenagon Asset Management S.A.
$89.8M1,280,194 sh
BANK OF AMERICA CORP /DE/
$83.8M1,194,377 sh

Fund	Value	Shares
Deep Track Capital, LP	$252.5M	3,600,000
BlackRock, Inc.	$249.2M	3,552,612
RTW INVESTMENTS, LP	$234.7M	3,346,025
Paradigm Biocapital Advisors LP	$179.7M	2,562,154
JANUS HENDERSON GROUP PLC	$157.2M	2,240,963
MORGAN STANLEY	$136.4M	1,944,272
VANGUARD CAPITAL MANAGEMENT LLC	$123.5M	1,760,541
JENNISON ASSOCIATES LLC	$120.1M	1,712,124
Assenagon Asset Management S.A.	$89.8M	1,280,194
BANK OF AMERICA CORP /DE/	$83.8M	1,194,377

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TARS on your watchlist

Track score changes the day Tarsus Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TARS a good stock to buy?

13F Pro's AI-powered analysis of Tarsus Pharmaceuticals, Inc. (TARS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TARS are available on the TARS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TARS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TARS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tarsus Pharmaceuticals, Inc.'s investment landscape.